References
- Foran JM. New prognostic markers in acute myeloid leukemia: perspective from the clinic. Hematology Am Soc Hematol Educ Program. 2010;2010:47–55.
- O’Donnell MR, Appelbaum FR, Coutre SE, Damon LE, Erma HP, Foran J, et al.. Acute myeloid leukemia: NCCN clinical practice guidelines in oncology — v.2·2010. National Comprehensive Cancer Network [Internet]; 2010.Available from: www.nccn.org. (accessed 24 Nov 201).
- Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, et al.. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 2010;17:13–27.
- Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O, et al.. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood. 2009;113:6215–24.
- Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, et al.. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301:2349–61.
- Schlenk RF, Dohner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, et al.. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358:1909–18.
- Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood. 2010;116:5089–102.
- Ravandi F. Gemtuzumab ozogamicin: one size does not fit all — the case for personalized therapy. J Clin Oncol. 2011;29:349–51.
- Rezvani K. Peptide vaccine therapy for leukemia. Int J Hematol. 2011;93:274–80.
- Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, et al.. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28:562–9.